NCT01281150

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Study identifier: NCT01281150
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

• Metastatic spread (stage IV) or locally advanced and unresectable
• Patients may have estrogen receptor positive or negative (ER+ or ER-) disease
• Patients with breast cancer may not be HER2-positive ( 3+), or FISH ratio > 2.2
• No uncontrolled CNS metastasis

Type of study:

Phase I

Treatment:

• Patients receive veliparib orally (PO) on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 3, 10, and 17. Courses repeat every 21 days in the absence of disease progression or toxicity.

Study site:

Pennsylvania

Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Contact: Clinical Trials Office - Penn State Hershey Cancer Institute     717-531-3779     CTO@hmc.psu.edu   

UPMC Cancer Center at Magee-Womens Hospital
Pittsburgh, Pennsylvania, 15213
Contact: Clinical Trials - UPMC Cancer Center at Magee-Womens Hospital  412-647-2811

Page updated 03/21/11

Web design by Rareheron Web Design